retatrutide while breastfeeding What are the considerations for using (glucagon-like peptide-1 receptor agonist) in women with type 2 diabetes or obesity? 🚨 New Research Alert: Tirzepatide

They are not Thailand-specific shortcuts

Month 1: 2-4% weight loss, appetite changes beginning Months 2-3: 6-10% cumulative loss, GI symptoms improving Months 4-6: 12-18% cumulative loss, stable dose reached Months 7-9: 18-22% cumulative loss, pace slowing Months 10-12: 20-24% cumulative loss, approaching plateau Plateau typically arrives around month 10-11

Serious side effects, such as pancreatitis or kidney problems, are rare but can occur

This approach allows the body to adjust to the medication while minimizing side effects

At the 3.0 mg daily dose, liraglutide produced average weight losses on the order of ~8% in pivotal trials (SCALE program), with additional benefits in glycemic measures and cardiometabolic risk markers

There is no reason to expect Retatrutide would be different